Search: onr:"swepub:oai:DiVA.org:uu-366942" > Recurrence, progres...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06049naa a2200685 4500 | |
001 | oai:DiVA.org:uu-366942 | |
003 | SwePub | |
008 | 181128s2018 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3669422 URI |
024 | 7 | a https://doi.org/10.1007/s00345-018-2299-22 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Palou, J.u Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain4 aut |
245 | 1 0 | a Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG :b not as bad as previously thought |
264 | c 2018-05-02 | |
264 | 1 | b SPRINGER,c 2018 |
338 | a print2 rdacarrier | |
520 | a Purpose: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG.Methods: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (71.4%): Ta in 378 (40.5%), T1 in 289 (30.9%) patients. Times to recurrence, progression and CSM in the three groups were estimated using cumulative incidence functions and compared using the Cox regression model.Results:During a median follow-up of 5.2years, 512 patients recurred. The recurrence rate was significantly higher in patients with a T1 at re-TUR (P<0.001). Progression rates differed according to the pathology at re-TUR, 25.3% in T1, 14.6% in Ta and 14.2% in case of no residual tumor (P<0.001). Similar trends were seen in both patients with and without muscle in the original TUR specimen.Conclusions: Patients with T1G3 tumors and no residual disease or Ta at re-TUR have better recurrence, progression and CSM rates than previously reported, with a CSM rate of 13.1 and a 25.3% progression rate in re-TUR T1 disease. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng |
653 | a Non-muscle invasive bladder cancer | |
653 | a Re-transurethral resection of the bladder | |
653 | a Recurrence | |
653 | a Progression | |
700 | 1 | a Pisano, F.u Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain;Osped Citta Salute & Sci Molinette, Dept Urol, Corso Bramante 88, I-10126 Turin, Italy4 aut |
700 | 1 | a Sylvester, R.u EORTC Headquarters, Dept Biostat, Brussels, Belgium4 aut |
700 | 1 | a Joniau, S.u Univ Hosp Leuven, Oncol & Reconstruct Urol, Dept Urol, Louvain, Belgium4 aut |
700 | 1 | a Serretta, V.u Univ Palermo, Dept Surg Oncol & Stomatol Sci, Palermo, Italy4 aut |
700 | 1 | a Larre, S.u Univ Oxford, John Radcliffe Hosp, Dept Surg Sci, Oxford, England4 aut |
700 | 1 | a Di Stasi, S.u Policlin Tor Vergata Univ Rome, Rome, Italy4 aut |
700 | 1 | a van Rhijn, B.u Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands4 aut |
700 | 1 | a Witjes, A. J.u Radboud Univ Nijmegen, Med Ctr, Dept Urol, Nijmegen, Netherlands4 aut |
700 | 1 | a Grotenhuis, A.u Radboud Univ Nijmegen, Med Ctr, Dept Urol, Nijmegen, Netherlands4 aut |
700 | 1 | a Colombo, R.u Univ Vita Salute, Osped S Raffaele, Dipartimento Urol, Milan, Italy4 aut |
700 | 1 | a Briganti, A.u Univ Vita Salute, Osped S Raffaele, Dipartimento Urol, Milan, Italy4 aut |
700 | 1 | a Babjuk, M.u Univ Praha, Motol Hosp, Dept Urol, Prague, Czech Republic4 aut |
700 | 1 | a Soukup, V.u Univ Praha, Motol Hosp, Dept Urol, Prague, Czech Republic4 aut |
700 | 1 | a Malmström, Per-Unou Uppsala universitet,Urologkirurgi4 aut0 (Swepub:uu)perunoms |
700 | 1 | a Irani, J.u Univ Poitiers, Dept Urol, Ctr Hosp Univ Mil, Poitiers, France4 aut |
700 | 1 | a Malats, N.u Spanish Natl Canc Res Ctr CNIO, Genet & Mol Epidemiol Grp, Madrid, Spain4 aut |
700 | 1 | a Baniel, J.u Rabin Med Ctr, Dept Urol, Tel Aviv, Israel4 aut |
700 | 1 | a Mano, R.u Rabin Med Ctr, Dept Urol, Tel Aviv, Israel4 aut |
700 | 1 | a Cai, T.u Santa Chiara Hosp, Dept Urol, Trento, Italy4 aut |
700 | 1 | a Cha, E. K.u Cornell Univ, Weill Med Coll, Dept Urol, New York, NY 10021 USA4 aut |
700 | 1 | a Ardelt, P.u Chirurg Univ Klin, Facharzt Urol, Urol Abt, Freiburg, Germany4 aut |
700 | 1 | a Varkarakis, J.u Univ Athens, Sismanoglio Hosp, Dept Urol, Athens, Greece4 aut |
700 | 1 | a Bartoletti, R.u Univ Florence, Dept Expt & Clin Med, Florence, Italy4 aut |
700 | 1 | a Dalbagni, G.u Mem Sloan Kettering Canc Ctr, Dept Urol, 1275 York Ave, New York, NY 10021 USA4 aut |
700 | 1 | a Shariat, S. F.u Med Univ Vienna, Vienna, Austria4 aut |
700 | 1 | a Xylinas, E.u Cochin Hosp, Dept Urol, Paris, France4 aut |
700 | 1 | a Karnes, R. J.u Mayo Clin, Dept Urol, Rochester, MN USA4 aut |
700 | 1 | a Gontero, P.u Osped Citta Salute & Sci Molinette, Dept Urol, Corso Bramante 88, I-10126 Turin, Italy4 aut |
710 | 2 | a Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spainb Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona, Spain;Osped Citta Salute & Sci Molinette, Dept Urol, Corso Bramante 88, I-10126 Turin, Italy4 org |
773 | 0 | t World journal of urologyd : SPRINGERg 36:10, s. 1621-1627q 36:10<1621-1627x 0724-4983x 1433-8726 |
856 | 4 | u https://art.torvergata.it/bitstream/2108/213079/1/World%20Journal%20of%20Urology%202018_36_1621_1627.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-366942 |
856 | 4 8 | u https://doi.org/10.1007/s00345-018-2299-2 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view